CALA OTC
Calithera Biosciences, Inc.
1W: -66.7%
1M: -66.7%
3M: -75.0%
YTD: +0.0%
1Y: +0.0%
3Y: -99.8%
5Y: -100.0%
$0.00
+0.00 (+0.00%)
Weekly Expected Move ±115.6%
$-0
$-0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$0
-100.0% ▼
Gross Profit
-$1M
-116.7% ▼
Operating Income
-$42M
+63.2% ▲
Net Income
-$19M
+83.6% ▲
EPS (Diluted)
$-7.94
+74.5% ▲
EBITDA
-$38M
+66.3% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $22M | $0 | $0 | $10M | $0 |
| YoY Growth | -14.3% | -100.0% | +0.0% | +0.0% | -100.0% |
| Cost of Revenue | $0 | $2M | $2M | $1M | $1M |
| Gross Profit | $22M | -$2M | -$2M | $8M | -$1M |
| Gross Margin | 100.0% | — | — | 85.3% | — |
| R&D Expenses | $66M | $76M | $71M | $103M | $29M |
| SG&A Expenses | $13M | $17M | $20M | $21M | $12M |
| Operating Expenses | $80M | $93M | $90M | $123M | $41M |
| Operating Income | -$57M | -$93M | -$91M | -$114M | -$42M |
| Operating Margin | -257.4% | — | — | -1172.1% | — |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$55M | -$90M | -$90M | -$115M | -$40M |
| Tax Expense | -$3M | $0 | $0 | $0 | $0 |
| Net Income | -$51M | -$86M | -$89M | -$115M | -$19M |
| Net Margin | -231.3% | — | — | -1180.4% | — |
| EPS (Diluted) | $-28.12 | $-36.50 | $-26.20 | $-31.16 | $-7.94 |
| EBITDA | -$57M | -$88M | -$88M | -$114M | -$38M |
| Shares Outstanding | 2M | 2M | 3M | 4M | 5M |